Prescribing guide
Uplizna (inebilizumab-cdon)Pre-infusion screening, premedication, dosing and prior authorization criteria for NMOSDFor prescribers and their offices treating neuromyelitis optica spectrum disorder (NMOSD): what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
No REMS. HBV, quantitative immunoglobulin and TB screening before dose 1, immunizations at least 4 weeks before, prior authorization, a site of care, and no active infection on each dose day.
Example PA threshold
FEP example: age 18 or older, anti-AQP4 antibody positive, no active HBV, no active or untreated latent TB, no concurrent live vaccines.
Monitoring
Premedicate every infusion; observe during and 1 hour after; infection check before each dose; immunoglobulins at baseline, during treatment and until B-cell repletion; HBV monitoring for at-risk patients.
Support line
Amgen By Your Side, Patient Access Liaison 1-833-842-8477; as little as $0 for drug and infusion costs on eligible commercial plans; no administration support for MA or RI residents.
Give your patient their plan
A one-page handout for starting Uplizna, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/upliznaBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| Enroll in Amgen By Your Side | Patient calls 1-833-842-8477, or the office starts enrollment on AmgenByYourSide.com and submits it with patient consent. A Patient Access Liaison is assigned. | Amgen By Your Side FAQ |
| Benefits investigation | After the patient signs a HIPAA release, the team reviews coverage and estimated out-of-pocket costs. It also checks whether PA is required and whether a medical exception with a letter of medical necessity is needed. | Amgen insurance page |
| Complete pre-dose screening | HBsAg and anti-HBV tests, quantitative serum immunoglobulins, TB risk evaluation and latent TB testing. Consider anti-TB therapy first for inadequately treated latent TB or risk factors with a negative test; consult infectious disease. | FDA label |
| Vaccines | All immunizations per guidelines at least 4 weeks before initiation (section 5.2; section 2.1 ties the window to live or live-attenuated vaccines). Not recommended during treatment or after discontinuation until B-cell repletion. | FDA label |
| Site of care | Infusion center or physician office; Amgen notes home infusion may be an option subject to the physician and the plan. Requires an experienced healthcare professional with access to support for severe reactions. | Starting Uplizna |
| Product and preparation | One carton of three 100mg/10mL single-dose vials (NDC 75987-150-03) per dose. Use a 21-gauge or smaller bore needle; no vial spikes or closed system transfer devices (added September 2026). Store diluted solution up to 24 hours refrigerated or 4 hours at room temperature before starting. | FDA label |
| Co-pay program | Amgen Commercial Co-Pay Program: commercial insurance with cost share, US residents, as little as $0 for drug and infusion costs; program maximums apply. Excludes Medicare, Medicare Part D, Medicaid, Medigap, VA, CHAMPUS, DOD, TRICARE, state or foundation coverage. | Amgen financial support |
| State exclusion | Residents of Massachusetts or Rhode Island are not eligible for administration support. Full terms at amgenbyyourside.com/copaytcs. | Uplizna HCP site |
| Denial path | Medical exception request or appeal through the office; Amgen By Your Side educates on both. Independent foundations listed by Amgen: The Assistance Fund, Good Days, PAN Foundation, NORD. | Amgen insurance page |
Prior authorization criteria and what to document
One public policy as the example: Blue Cross Blue Shield Federal Employee Program, April 1, 2026. Approval twelve months at first, up to 9 vials. Renewals are 12 months at a time, up to 6 vials, when the neurologist documents a clinical benefit such as fewer relapses. This policy was approved on March 6, 2026 and cites the December 2025 label. It predates the September 2026 label, which changed only how pharmacists draw the medicine from the vial. Nothing in it conflicts with the current label. It is here as an example of what a plan asks for, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Diagnosis | Neuromyelitis optica spectrum disorder, age 18 or older | Diagnosis in the note | FEP Blue policy |
| Serology | Anti-aquaporin-4 (AQP4) antibody positive | Antibody result with date | FEP Blue policy |
| Hepatitis B | No active hepatitis B infection | HBV screening results | FEP Blue policy |
| Tuberculosis | No active or untreated latent tuberculosis | TB test result and any treatment history | FEP Blue policy |
| Vaccines | Not given concurrently with live vaccines | Vaccine history and plan | FEP Blue policy |
| Contraception | Females of reproductive potential advised on effective contraception during treatment and 6 months after the last dose | Counseling note | FEP Blue policy |
| Renewal | Clinical benefit, for example fewer relapses or improvement in flares; first approval 12 months and 9 vials, renewals 12 months and 6 vials | Relapse history since start | FEP Blue policy |
Uplizna dosing and titration
| When | Label | Source |
|---|---|---|
| Day 1 | 300mg IV, titrated to completion over about 90 minutes. | FDA label |
| Day 15 | 300mg IV, 2 weeks after the first infusion. | FDA label |
| Every 6 months | 300mg IV, starting 6 months from the first infusion. | FDA label |
| Infusion rate (250mL bag) | 42mL/hour for minutes 0 to 30, 125mL/hour for minutes 31 to 60, 333mL/hour from minute 61 to completion. Bring the prepared solution to room temperature first. | FDA label |
| Premedication, every infusion | Corticosteroid IV 30 minutes before (methylprednisolone 80 to 125mg or equivalent). Antihistamine (diphenhydramine 25 to 50mg) and antipyretic (acetaminophen 500 to 650mg) orally 30 to 60 minutes before. | FDA label |
| Reaction management | Life-threatening or disabling reaction: stop immediately and permanently, give supportive care. Less severe: pause, slow the rate and/or treat symptoms. | FDA label |
| Pediatric and geriatric | Safety and effectiveness not established under 18. NMOSD trials had too few patients 65 and older to assess differences. | FDA label |
| Other indications | IgG4-RD (April 2025) and AChR or MuSK antibody positive gMG (December 2025) use the same schedule; not covered on this page. | FDA letter |
Monitoring the Uplizna label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Before dose 1 | HBV, quantitative serum immunoglobulins, TB | Contraindicated with active HBV or active or untreated latent TB; hepatology consult for HBsAg-negative HBcAb-positive or HBsAg-positive; immunology consult if immunoglobulins are low | FDA label |
| Each infusion | Infusion reactions, including anaphylaxis: headache, nausea, somnolence, dyspnea, fever, myalgia, rash, palpitations | Observe during and at least 1 hour after. 9.3% in the NMOSD randomized period; most common with the first infusion | FDA label |
| Before each dose | Active infection | Delay until resolved. Across NMOSD randomized and open-label periods: UTI 20%, nasopharyngitis 13%, URTI 8%, influenza 7% | FDA label |
| During treatment and after stopping | Quantitative serum immunoglobulins | NMOSD: IgG below LLN in 7% at year 1 and 13% at year 2; IgM below LLN in 31% and 42%. Consider discontinuing with serious opportunistic or recurrent infections, or hypogammaglobulinemia needing IVIG | FDA label |
| At-risk patients | HBV reactivation | Fulminant hepatitis, hepatic failure and death reported with B-cell depleting therapies; reactivation seen with Uplizna in the gMG trial and postmarketing | FDA label |
| Ongoing | PML symptoms or MRI findings | Withhold at the first sign and evaluate. No confirmed cases in trials; 1 death after new lesions with PML in the differential | FDA label |
| Randomized period | Neutrophils | NMOSD: 1.0 to 1.5 x 10^9/L in 7% against 2% placebo; 0.5 to 1.0 in 2% against 0% | FDA label |
Uplizna drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| Immunosuppressants, including systemic corticosteroids | May increase infection risk; consider additive immune effects. Immunosuppressants and routine corticosteroids were prohibited in the NMOSD blinded period | FDA label |
| Vaccines | All immunizations at least 4 weeks before initiation; live or live-attenuated vaccines not recommended during treatment or until B-cell repletion | FDA label |
| Infants exposed in utero | No live or live-attenuated vaccines until infant B-cell recovery is confirmed; non-live vaccines may be given, consider specialist input on response | FDA label |
| Pregnancy | Fetal B-cell depletion and lasting immune effects in mice; contraception during treatment and 6 months after the last dose. Pregnancy registry 1 (303) 724-4644 | FDA label |
| Lactation | No human data; human IgG is excreted in milk, effect on infant B cells unknown | FDA label |
| Contraindicated | Prior life-threatening infusion reaction to Uplizna, active hepatitis B, active or untreated latent tuberculosis | FDA label |
Why a first fill stalls, and the fix
- Prior authorization pending or deniedThe FEP policy below asks for age 18 or older and a positive AQP4 antibody test. It also asks for no active hepatitis B, no active or untreated latent tuberculosis and no live vaccines given at the same time. The neurologist's records usually answer what the plan is asking for.
- Screening results are missingHepatitis B, tuberculosis and antibody level results are required before the first dose. Amgen says your liaison can help with steps such as completing required labs and checking what the prior authorization still needs.
- The plan says no after reviewAmgen describes 2 next steps. Your doctor can ask for a medical exception with extra paperwork, or you and the office can appeal. The Amgen By Your Side team can explain both.
- A copay you cannot payCommercial insurance: the Amgen Commercial Co-Pay Program, as little as $0 for Uplizna and infusion costs, with program maximums. Medicare, Medicaid, VA, TRICARE and other government coverage are excluded. Our help paying page lists charity funds that may cover what remains.
- You live in Massachusetts or Rhode IslandAmgen's co-pay terms say residents of these 2 states are not eligible for administration support. Help with the medicine itself may still apply, so the clinic fee may fall on you.
- Medicare, Medicaid or no insuranceThe co-pay program does not apply. Amgen lists independent funds such as The Assistance Fund, Good Days, the PAN Foundation and NORD. Each sets its own rules, and Amgen does not run them.
- The renewal after a yearThe FEP policy renews for 12 months at a time, with 6 vials, when your neurologist documents a benefit such as fewer relapses. Ask the office when the renewal is due so the 6-month dose is not delayed.
Amgen By Your Side
- A dedicated Patient Access Liaison who explains insurance, costs and appointments, and helps find an infusion center
- A benefits investigation after you sign a HIPAA release: what your plan covers, your likely costs and whether a prior authorization is needed
- The Amgen Commercial Co-Pay Program, as little as $0 for Uplizna and infusion costs for eligible commercial insurance, with program maximums Uplizna HCP site
- Co-pay help is not open to Medicare, Medicaid, Medigap, VA, CHAMPUS, DOD, TRICARE or other government coverage, under the program's terms
- Residents of Massachusetts or Rhode Island are not eligible for the infusion administration part of the co-pay help Amgen financial support
- A list of independent charity funds Amgen financial support
- NMOSD Peer Mentors, Uplizna patients who volunteer to talk about their own experience Personalized support
Questions prescribers' offices ask about Uplizna
What is the Uplizna dose for NMOSD?
The September 2026 label gives 300mg IV on day 1, 300mg IV 2 weeks later, then 300mg IV every 6 months counted from the first infusion. Dilute all 3 100mg/10mL vials (30mL) in 250mL 0.9% sodium chloride. Infuse by pump through a 0.2 or 0.22 micron in-line filter at 42, 125, then 333mL/hour, about 90 minutes.
What screening is required before the first Uplizna dose?
Three assessments, per the September 2026 label: HBV screening, quantitative serum immunoglobulins and TB evaluation with latent infection testing. Active HBV and active or untreated latent TB are contraindications; HBsAg-negative, HBcAb-positive patients or HBV carriers need hepatology input, low immunoglobulins need immunology input. Give all immunizations per guidelines at least 4 weeks before initiation; live vaccines are not recommended during treatment.
What premedication does Uplizna need?
Three agents before every infusion, per the September 2026 label. Give a corticosteroid IV 30 minutes prior (example methylprednisolone 80 to 125mg). Give an antihistamine (diphenhydramine 25 to 50mg) and an antipyretic (acetaminophen 500 to 650mg) orally 30 to 60 minutes prior. Infusion reactions occurred in 9.3% in the NMOSD randomized period, most often with the first infusion.
What monitoring does Uplizna need?
Close observation during and for at least 1 hour after each infusion, per the September 2026 label, plus an active-infection check before every dose. Monitor quantitative immunoglobulins during treatment and after discontinuation until B-cell repletion, especially with recurrent or opportunistic infections. Withhold at the first sign of PML.
What do insurers ask for to approve Uplizna for NMOSD?
The FEP policy shown here took effect April 1, 2026 and cites the December 2025 label. It asks for age 18 or older and AQP4 antibody positivity. It also requires no active HBV, no active or untreated latent TB, no concurrent live vaccines and contraception counseling. It approves 9 vials for 12 months, then 6 vials per 12 months with documented clinical benefit.
Free email alert
Get an email when the Uplizna label changes
One email the day the FDA revises the Uplizna prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Uplizna only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- DailyMed - UPLIZNA- inebilizumab injection (prescribing information revised September 2026, SPL version 11, and Medication Guide), Horizon Therapeutics USA (Amgen), via DailyMed, 2026-09-21.
- Cost, Savings, and Support | UPLIZNA® (inebilizumab-cdon), Amgen, 2026-11-07.
- UPLIZNA® Insurance Coverage | Amgen By Your Side, Amgen, 2026-11-07.
- UPLIZNA® Financial Support Programs | Amgen By Your Side, Amgen, 2026-11-07.
- Frequently Asked Questions (FAQs) for UPLIZNA® | Amgen By Your Side, Amgen, 2026-11-07.
- NMOSD: Starting UPLIZNA® (inebilizumab-cdon) | UPLIZNA®, Amgen, 2026-11-07.
- NMOSD Treatment | UPLIZNA® (inebilizumab-cdon), Amgen, 2026-11-07.
- NMOSD Personalized Support | UPLIZNA® (inebilizumab-cdon), Amgen, 2026-11-07.
- UPLIZNA® (inebilizumab-cdon) | Healthcare Professional Home, Amgen, 2026-11-07.
- Pharmacy Policy 5.99.018, Uplizna, Blue Cross Blue Shield Federal Employee Program, 2026-04-01.
- BLA 761142/S-004 supplement approval letter, generalized myasthenia gravis, FDA, 2025-12-11.
- BLA 761142 approval letter, Uplizna (inebilizumab-cdon) for NMOSD, FDA, 2020-06-11.
- BLA 761142/S-003 supplement approval letter, immunoglobulin G4-related disease, FDA, 2025-04-03.
A reference drawn from the September 21, 2026 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 7, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.